Cas:22326-31-4 5-Sulfoisophthalic acid manufacturer & supplier

We serve Chemical Name:5-Sulfoisophthalic acid CAS:22326-31-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-Sulfoisophthalic acid

Chemical Name:5-Sulfoisophthalic acid
CAS.NO:22326-31-4
Synonyms:3,5-dicarboxybenzenesulfonic acid;5-Sulfoisophthalicacid;1,3-Benzenedicarboxylic acid,5-sulfo;5-Sulphoisophthalic acid;1,3-Benzenedicarboxylic acid, 5-sulfo-;5-sulfobenzene-1,3-dicarboxylic acid;5-sulfo-1,3-benzenedicarboxylate;5-Sulfaisophalic acid (5-SIPA);EINECS 244-912-9;MFCD00066788;5-Sulfo-1,3-benzenedicarboxylic acid;5-Sulfoisophthalic acid
Molecular Formula:C8H6O7S
Molecular Weight:246.194
HS Code:2917399090

Physical and Chemical Properties:
Melting point:249-253 °C
Boiling point:N/A
Density:1.8±0.1 g/cm3
Index of Refraction:1.643
PSA:137.35000
Exact Mass:245.983429
LogP:0.71

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3,5-dicarboxybenzenesulfonic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Sulfoisophthalic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Sulphoisophthalic acid Use and application,3,5-dicarboxybenzenesulfonic acid technical grade,usp/ep/jp grade.


Related News: If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such. 5-Sulfoisophthalic acid manufacturer For example, there are concerns that PFAS’ effect on the thyroid could lead to thyroid cancer, van Gerwen said. 5-Sulfoisophthalic acid supplier The findings were published June 14 in the journal Nature Aging. 5-Sulfoisophthalic acid vendor If the drug is in a syrup form, then the excipient is the liquid that has been used to make it as such. 5-Sulfoisophthalic acid factory Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease.